This study aimed to evaluate whether XPC A2920C, XPF T30028C, TP53 Arg72Pro, and GSTP1 Ile105Val polymorphisms alter outcomes of cutaneous melanoma (CM) patients. DNA from 237 CM patients seen at the University of Campinas Teaching Hospital from April 2000 to February 2014 was analyzed by polymerase chain reaction and restriction fragment length polymorphism assays. The prognostic impact of genotypes of polymorphisms on progression-free survival (PFS) and overall survival (OS) of CM patients were examined using the Kaplan-Meier probability estimates and univariate and multivariate Cox regression analyses. At 60 months of follow-up, shorter PFS and OS were seen in patients with XPF CC genotype (48.9 vs. 66.7 %, P = 0.002; 77.9 vs. 83.5 %, P = 0.006, respectively) and XPF CC + TP53 ArgArg (43.6 vs. 65.9 %, P = 0.007; 71.6 vs. 84.8 %, P = 0.006, respectively) compared with those with remaining genotypes (Kaplan-Meier estimates). Patients with XPF CC (hazard ratio (HR) 2.45, P = 0.002; HR 3.77, P = 0.005) and XPF CC + TP53 ArgArg (HR 2.67, P = 0.009; HR 4.04, P = 0.03) genotypes had more chance to present tumor progression in univariate and multivariate analyses, whereas patients with XPF CC (HR 2.78, P = 0.009) and XPF CC + TP53 ArgArg (HR 3.84, P = 0.01) genotypes were under greater risk of progressing to death in univariate analysis, compared with those with the remaining genotypes. The data suggest, for the first time, that inherited abnormalities in DNA repair pathway related to XPF 30028C and TP53 Arg72Pro polymorphisms act as prognostic factors for PFS and OS of CM patients.
Cutaneous melanoma DNA repair Survival Genetic polymorphism
This is a preview of subscription content, log in to check access.
Compliance with Ethical Standards
Conflicts of interest
São Paulo Research Foundation (FAPESP) (grant no. 2009/12602-0, no. 2010/18904-5, and no. 2014/10042-5) funded this study. The funding source had no involvement in the design of the study, in the collection, analysis, interpretation of the data, and writing of the manuscript.
Instituto Nacional do Câncer (INCA/2014), htp://www.inca.org.br. Accessed 10 January 2015.
Buettner PG, Leiter U, Eigentler TK, Garbe C. Development of prognostic factors and survival in cutaneous melanoma over 25 years: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Cancer. 2005;103:616–24. doi:10.1002/cncr.20816.CrossRefPubMedGoogle Scholar
Spatz A, Stock N, Batist G, van Kempen LC. The biology of melanoma prognostic factors. Discov Med. 2010;10:87–93.PubMedGoogle Scholar
Dusinska M, Staruchova M, Horska A, Smolkova B, Collins A, Bonassi S, et al. Are glutathione S transferases involved in DNA damage signalling? Interactions with DNA damage and repair revealed from molecular epidemiology studies. Mutat Res Mol Mech Mutagen. 2012;736:130–7. doi:10.1016/j.mrfmmm.2012.03.003.CrossRefGoogle Scholar
Winsey SL, Haldar NA, Marsh HP, Bunce M, Marshall SE, Harris AL, et al. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res. 2000;60:5612–6.PubMedGoogle Scholar
Oliveira C, Rinck-Junior JA, Lourenço GJ, Moraes AM, Lima CSP. Assessment of the XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro) and GSTP1 (Ile105Val) polymorphisms in the risk of cutaneous melanoma. J Cancer Res Clin Oncol. 2013;139:1199–206. doi:10.1007/s00432-013-1430-4.CrossRefPubMedGoogle Scholar
Shi TY, He J, Qiu LX, Zhu ML, Wang MY, Zhou XY, et al. Association between XPF polymorphisms and cancer risk: a meta-analysis. PLoS One 2012;7. doi:10.1371/journal.pone.0038606.
Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 1987;7:961–3.CrossRefPubMedPubMedCentralGoogle Scholar
Dumont P, Leu JI-J, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–65. doi:10.1038/ng1093.CrossRefPubMedGoogle Scholar
Zimniak P, Nanduri B, Pikuła S, Bandorowicz-Pikuła J, Singhal SS, Srivastava SK, et al. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem. 1994;224:893–9.CrossRefPubMedGoogle Scholar
Rigel DS, Friedman RJ, Levenstein MJ, Greenwald DI. Relationship of fluorescent lights to malignant melanoma: another view. J Dermatol Surg Oncol. 1983;9:836–8.CrossRefPubMedGoogle Scholar
Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010;102:493–501. doi:10.1093/jnci/djq009.CrossRefPubMedGoogle Scholar
Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012;13:589–97. doi:10.1016/S1470-2045(12)70138-9.CrossRefPubMedGoogle Scholar
Honma HN, De Capitani EM, Perroud MW, Barbeiro AS, Toro IFC, Costa DB, et al. Influence of p53 codon 72 exon 4, GSTM1, GSTT1 and GSTP1*B polymorphisms in lung cancer risk in a Brazilian population. Lung Cancer. 2008;61:152–62. doi:10.1016/j.lungcan.2007.12.014.CrossRefPubMedGoogle Scholar
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time 1 quantitative PCR and the 2(−delta delta C(T)) method. Methods. 2001;25:402–8.CrossRefPubMedGoogle Scholar
Beiguelman B. Dinâmica dos Genes nas Famílias e Populações. Ribeirão Preto, Sociedade Brasileira de Genética. 1995;2:1–472.Google Scholar
Jekel JF, Katz DL and Elmore JG. Epidemiology, biostatistics and preventive medicine, 2nd ed, 2001;175–181.Google Scholar
Schrama D, Scherer D, Schneider M, Zapatka M, Bröcker E-B, Schadendorf D, et al. ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanoma. J Invest Dermatol. 2011;131:1280–90. doi:10.1038/jid.2011.35.CrossRefPubMedGoogle Scholar
Yokoi M, Masutani C, Maekawa T, Sugasawa K, Ohkuma Y, Hanaoka F. The xeroderma pigmentosum group C protein complex XPC-HR23B plays an important role in the recruitment of transcription factor IIH to damaged DNA. J Biol Chem. 2000;275:9870–5. doi:10.1074/jbc.275.13.9870.CrossRefPubMedGoogle Scholar
Zhu XD, Niedernhofer L, Kuster B, Mann M, Hoeijmakers JHJ, De Lange T. ERCC1/XPF removes the 3′ overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes. Mol Cell. 2003;12:1489–98. doi:10.1016/S1097-2765(03)00478-7.CrossRefPubMedGoogle Scholar
Cotignola J, Chou JF, Roy P, Mitra N, Busam K, Halpern AC, et al. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma. J Invest Dermatol. 2012;132:1471–8. doi:10.1038/jid.2012.15.CrossRefPubMedGoogle Scholar
Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A, Dessen P, et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene. 2008;27:565–73. doi:10.1038/sj.onc.1210700.CrossRefPubMedGoogle Scholar